Heron Therapeutics
HRTX

Heron Therapeutics (HRTX) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
HC Wainwright & Co.DowngradedBuy → NeutralAug 11, 2026
NeedhamDowngradedBuy → HoldJun 3, 2026
HC Wainwright & Co.MaintainedBuy$2.00 from $4.00Jun 3, 2026
HC Wainwright & Co.MaintainedBuy$6.00Jan 9, 2026
NeedhamMaintainedBuy$3.00 from $4.00Aug 8, 2025
HC Wainwright & Co.Initiated CoverageBuy$6.00Jun 9, 2025
NeedhamMaintainedBuy$4.00Apr 11, 2025
NeedhamMaintainedBuy$4.00Feb 28, 2025
NeedhamMaintainedBuy$4.00Dec 4, 2024
NeedhamMaintainedBuy$4.00 from $5.00Nov 13, 2024
NeedhamMaintainedBuy$5.00Sep 25, 2024
NeedhamMaintainedBuy$5.00Aug 7, 2024
Rodman & RenshawInitiated CoverageBuy$7.00Jun 13, 2024
NeedhamMaintainedBuy$5.00May 16, 2024
NeedhamMaintainedBuy$5.00May 8, 2024
Capital OneInitiated CoverageOverweight$6.00Apr 23, 2024
NeedhamMaintainedBuy$5.00Apr 11, 2024
NeedhamMaintainedBuy$5.00 from $4.00Mar 13, 2024
NeedhamMaintainedBuy$4.00 from $5.00Nov 15, 2023
NeedhamMaintainedBuy$5.00Aug 15, 2023

Frequently asked questions

  • What is the latest analyst rating on HRTX?

    On Aug 11, 2026, HC Wainwright & Co. downgraded Heron Therapeutics to Neutral.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.